382 related articles for article (PubMed ID: 32777728)
1. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
3. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
4. Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?-a meta-analysis of randomized controlled trials.
Dong H; Yao L; Wang M; Wang M; Li X; Sun X; Yu X; Guo J; Li X; Xu Y
Transl Cancer Res; 2020 Nov; 9(11):7034-7043. PubMed ID: 35117309
[TBL] [Abstract][Full Text] [Related]
5. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
[TBL] [Abstract][Full Text] [Related]
6. Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
Lin H; Liang G; Wu Y; Chen L
Cardiology; 2021; 146(4):469-480. PubMed ID: 33946067
[TBL] [Abstract][Full Text] [Related]
7. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials.
Fang K; Zhang Y; Liu W; He C
Heart Fail Rev; 2021 Jan; 26(1):101-109. PubMed ID: 31900787
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis.
Tang J; Wang P; Liu C; Peng J; Liu Y; Ma Q
Chin Med J (Engl); 2024 May; ():. PubMed ID: 38811344
[TBL] [Abstract][Full Text] [Related]
11. Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Sarocchi M; Arboscello E; Ghigliotti G; Murialdo R; Bighin C; Gualandi F; Sicbaldi V; Balbi M; Brunelli C; Spallarossa P
Chemotherapy; 2018; 63(6):315-320. PubMed ID: 30840967
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
14. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
Keshavarzian E; Sadighpour T; Mortazavizadeh SM; Soltani M; Motevalipoor AF; Khamas SS; Moazen M; Kogani M; Amin Hashemipour SM; Hosseinpour H; Valizadeh R
Rev Recent Clin Trials; 2023; 18(2):112-122. PubMed ID: 36803186
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
Yang Y; Wang R; Li MX; Xing Y; Li WG
Int J Cardiol; 2016 Sep; 219():350-7. PubMed ID: 27352206
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis.
Zhao M; Wang R; Yu Y; Chang M; Ma S; Zhang H; Qu H; Zhang Y
Front Pharmacol; 2021; 12():638611. PubMed ID: 34025408
[No Abstract] [Full Text] [Related]
18. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
20. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
